Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2021 Financial Results and Business Updates
Mersana Therapeutics (NASDAQ:MRSN) announced a conference call on August 6, 2021, at 8:00 a.m. ET to report its Q2 2021 financial results and provide business updates. The company focuses on developing antibody-drug conjugates (ADCs) for cancer treatment, with its lead candidate, upifitamab rilsodotin (UpRi), under investigation for platinum-resistant ovarian cancer and non-small cell lung cancer (NSCLC). Mersana’s platform is also supporting ADC development for multiple partners, highlighting its commitment to innovation in cancer therapies.
- Mersana’s lead product candidate, UpRi, is in a registration strategy for platinum-resistant ovarian cancer.
- The company also has promising ADC candidates, including XMT-1592, XMT-1660, and XMT-2056, showing potential for diverse cancer treatments.
- None.
CAMBRIDGE, Mass., July 30, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will host a conference call and webcast on Friday, August 6, 2021 at 8:00 a.m. ET to report financial results for the second quarter ended June 30, 2021 and provide business updates.
To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 3876353. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a single-arm registration strategy, in patients with platinum-resistant ovarian cancer as well as in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with NSCLC adenocarcinoma. XMT-1592, Mersana’s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company’s early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Company’s Immunosynthen platform. In addition, multiple partners are using Mersana’s Dolaflexin platform to advance their ADC pipelines.
Contact:
Investor & Media Contact
Sarah Carmody, 617-844-8577
scarmody@mersana.com
FAQ
When will Mersana Therapeutics report its Q2 2021 financial results?
What is the significance of upifitamab rilsodotin for Mersana Therapeutics?
Which other ADC candidates is Mersana developing?
How can investors access the Mersana conference call?
